SWOG clinical trial number
S0020
A PHASE II STUDY OF ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
Closed
Phase
Accrual
16%
Research committees
Leukemia
Treatment
Anti-thymocyte globulin
Eligibility Criteria Expand/Collapse
Morphologically confirmed diagnosis of MDS in one of the following subclassifications: RA, RARS, RAEB and be in one of the following International Prognostic Scoring System (IPSS) risk categories: low, intermediate-1, intermediate-2; no previous BM or SC transplant, no prior chemotherapy for MDS. Patients must have received transfusions of at least 4 units of red blood cells as supportive care for anemia during the 60 days before registration; PS 0-2, HIV negative.
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/A042001
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
Accrual
40%
Open
Phase
SWOG Clinical Trial Number
CTSU/AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Research Committee(s)
Leukemia
Activated
12/04/2020
Open